Rojananuangnit Kulawan, Sudjinda Nuttawan
Glaucoma Unit, Ophthalmology Department, Mettapracharak (Wat Rai Khing) Hospital, Nakhon Pathom, Thailand.
Clin Ophthalmol. 2021 Feb 25;15:835-843. doi: 10.2147/OPTH.S300226. eCollection 2021.
Utility index is a significant outcome in terms of health economics assessment while patient-reported outcome measure (PROMs) evaluates quality of life (QOL) from patient's perspective. Our objective was to evaluate both utility indices and PROMs using generic and eye specific QOL in glaucomatous patients compared with normal population.
This is a case-control study. We interviewed normal and glaucomatous participants with the European Quality of Life questionnaire (EQ-5D-5L), the European visual analogue scale (EQ-VAS) and the visual function questionnaire 28 (Thai version) (VFQ-28). The visual function questionnaire utility index (VFQ-UI) and generic utility index from EQ-5D-5L were calculated.
There were 47 normal and 127 glaucomatous participants in this study. Amongst glaucoma group, 35 participants were in the early stage of the disease, 43 were in the moderate stage, 30 normal vision participants were in the severe stage, 14 participants had blindness one eye, and 5 had blindness both eyes. The mean age of the participants in both groups was statistically similar (63.78±6.84 vs 66.30±8.93 years old, respectively, p=0.062). Underlying diseases between groups were also comparable. The EQ-5D-5L utility index score and the EQ-VAS score were not statistically different between normal and glaucomatous groups, respectively (EQ-5D-5L: 0.874±0.122 vs 0.837±0.191, p=0.215; EQ VAS: 76.06±15.07 vs 74.02 ±15.10, p=0.43). By contrast, VFQ-UI of the glaucomatous group was significantly lower than that of the normal group, (VFQ-UI: 0.833±0.147 vs 0.895±0.070, accordingly, p<0.05).
Utility index from the VFQ-UI was a relevant PROMs for evaluating the QOL of glaucomatous patients in terms of visual function specificity and acceptable validity.
效用指数是健康经济学评估的一项重要结果,而患者报告结局测量(PROMs)从患者角度评估生活质量(QOL)。我们的目的是使用通用和眼部特异性生活质量评估青光眼患者与正常人群的效用指数和PROMs。
这是一项病例对照研究。我们使用欧洲生活质量问卷(EQ-5D-5L)、欧洲视觉模拟量表(EQ-VAS)和视觉功能问卷28(泰语版)(VFQ-28)对正常和青光眼参与者进行访谈。计算视觉功能问卷效用指数(VFQ-UI)和EQ-5D-5L的通用效用指数。
本研究中有47名正常参与者和127名青光眼参与者。在青光眼组中,35名参与者处于疾病早期,43名处于中期,30名视力正常的参与者处于晚期,14名参与者单眼失明,5名双眼失明。两组参与者的平均年龄在统计学上相似(分别为63.78±6.84岁和66.30±8.93岁,p = 0.062)。两组之间的基础疾病也具有可比性。正常组和青光眼组的EQ-5D-5L效用指数得分和EQ-VAS得分在统计学上无差异(EQ-5D-5L:0.874±0.122 vs 0.837±0.191,p = 0.215;EQ VAS:76.06±15.07 vs 74.02±15.10,p = 0.43)。相比之下,青光眼组的VFQ-UI显著低于正常组(VFQ-UI:0.833±0.147 vs 0.895±0.070,因此,p<0.05)。
VFQ-UI的效用指数在视觉功能特异性和可接受的有效性方面是评估青光眼患者生活质量的一个相关PROMs。